MerlinTrader

Educational/info only — not financial advice and not a buy/sell recommendation. I may hold positions in mentioned securities and may trade at any time without notice. Posts reflect my personal views and can be wrong. Verify with official sources. Trading/investing is high risk and can result in total loss. Full disclaimer: merlintrader.com/disclaimer/

$XERS Latest company news, Oct 22: Q3 results scheduled for Nov 5 before the open, call 8:30 a.m. ET. Nov 6: ATA presentation of an observational analysis (not an XP-8121 efficacy readout). Rebuilt free hub + 23-page PDF: merlintrader.com/xeris-bioph… Not investment advice.

$VERA Latest company news, Oct 24: ASN PIONEER abstract, exploratory proteinuria reductions (open-label, small groups). Next: Nov 4 Oxford tranche draw window ends; Nov 5 Q3 webcast. Rebuilt free hub + 21-page PDF: merlintrader.com/vera-therap… Not investment advice.

$SRPT Next: Q3 results Nov 5, call 4:30 p.m. ET after the close. Oct 26: two investor conferences on Nov 9. Rebuilt free hub + 26-page PDF report: merlintrader.com/sarepta-the… Not investment advice.

$SNDL Latest company news, Oct 28: preliminary issuer-bid communication (TO-C); the bid has not commenced. Next: Nov 5 optional DEA replies (procedural, not a rescheduling decision). Rebuilt free hub + 23-page PDF report: merlintrader.com/sndl-stock-… Not investment advice.

$SMMT Next: special meeting Nov 4 on raising authorized shares from 1B to 2B; FDA review goal date Nov 14 (not a promise of approval). Oct 25: China HARMONi-GI1 interim OS 14.9 vs 12.1 months. Rebuilt free hub + 21-page PDF report: merlintrader.com/summit-ther… Not investment advice.

$RZLV Latest company news, Oct 20: Revolut agreement opens a Reward channel; no revenue or terms disclosed. Monroe term loan matures Dec 31, 2026. Rebuilt free hub + 26-page PDF report: merlintrader.com/rezolve-ai-… Not investment advice.

$RKLB Latest company news, Oct 27: eight of 18 Tranche 2 spacecraft in build (existing award). Next: financial update Nov 9 after the close. Rebuilt free hub + 26-page PDF report: merlintrader.com/rocket-lab-… Not investment advice.

$PLUG Next: Q3 results and call Nov 9, 4:30 p.m. ET (Oct 15 figures were preliminary and unaudited). Oct 19 Form 4: 9,375 shares sold at $1.41 under a 10b5-1 plan. Rebuilt free hub + 22-page PDF report: merlintrader.com/plug-power-… Not investment advice.

$OTLK Next: U.S. launch of LYTENAVA planned before Dec 31, 2026 (a company plan). Oct 13: Empery's 13G reports 8.73% (21,247,856 shares) as of Sep 30. Rebuilt free hub + 26-page PDF report: merlintrader.com/outlook-the… Not investment advice.

$OMER Latest company news, Oct 16: EMA record confirms the CHMP refusal recommendation after re-examination; Omeros disputes the process (company account). Next: Q3 results, date not announced. Rebuilt free hub + 45-page PDF report: merlintrader.com/omeros-corp… Not investment advice.

$OCUL Latest company news, Oct 29: November appearances set (Nov 5, 6-8, 17); no NDA filing or new data announced. Next: AXPAXLI NDA submission plan, Q4 2026 (a plan, not an accepted NDA). Rebuilt free hub + 20-page PDF report: merlintrader.com/ocular-ther… Not investment advice.

$NRXP Oct 29: call set for 8:30 a.m. ET on Oct 30 about a Preservative-Free Ketamine regulatory milestone; details due in a release before the open (not an approval by itself). ANDA goal date: Nov 10. Rebuilt hub + 42-page PDF: merlintrader.com/nrx-pharmac… Not investment advice.

$MDA Q3 results Nov 5 before the open, call 8:30 a.m. ET. Oct 28: 49North qualified for all five DDI Marketplace streams (eligibility, not an award). CHORUS launch targeted late 2026. Rebuilt hub + 22-page PDF: merlintrader.com/mda-space-m… Not investment advice.

$IBRX Next: QUILT-2.005 topline, guided to November (no exact day). Oct 21: database lock for 366 patients; sBLA planned for Q4. Procedural step, not an efficacy result. Rebuilt free hub + 50-page PDF report: merlintrader.com/immunitybio… Not investment advice.

$HYLN Latest company news, Oct 28: Q3 results after the close on Nov 10, call Nov 11 at 11:00 a.m. ET. To watch: spending, financing, early-adopter deployments. Rebuilt free hub + 23-page PDF report: merlintrader.com/hyliion-hol… Not investment advice.

$HTZ Q3 results are due Nov 5 at 8:00 a.m. ET. Oct 27: BlackRock's 13G/A shows 3.3% as of Sep 30. The December $200M maturity was guided to be paid in cash (not confirmed). Rebuilt free hub + 24-page PDF report: merlintrader.com/hertz-globa… Not investment advice.

$HELP Next: APPROACH topline guided to Q4 2026. Oct 27: both co-founders left executive roles but remain directors, and an independent director became Chair (governance, not a clinical result). Rebuilt free hub + 23-page PDF report: merlintrader.com/helus-pharm… Not investment advice.

$GERN Latest company news, Oct 28: Phase 3 IMpactMF discontinued after the DMC advised it was unlikely to meet its OS primary endpoint; no new safety signals. Next: Q3 earnings Nov 4 pre-market. Rebuilt free hub + 45-page PDF report: merlintrader.com/geron-corpo… Not investment advice.

$DRTS Latest company news, Oct 29: ordinary shares join the TASE TA-90 and TA-125 indices on Nov 5 (separate from clinical progress). Next clinical date: REGAIN at SNO, Nov 13. Rebuilt free hub + 23-page PDF report: merlintrader.com/alpha-tau-s… Not investment advice.

$LAC Thacker Pass energization targeted for Q4 2026 (not a completion). Q3 results estimated Nov 13. Oct 26: six Form 4s show RSU settlements, not open-market buying. Rebuilt hub + 19-page PDF: merlintrader.com/lithium-ame… Not investment advice.